Abstract-RNA sequencing, or RNA-seq for short, is widely applied for extracting gene and transcript expression from biological samples. Given numerous quantification pipelines for RNA-seq data, one fundamental challenge is to identify a pipeline that can produce the most accurate gene and/or transcript expression. Exploring all pipelines requires extensive computational resources, so we propose to use a subsampling approach that can speed up the pipeline evaluation and selection process. We applied our approach to one simulated and two real RNA-seq datasets and found that expression estimates derived from subsampled data are close surrogates for those derived from original data. In addition, the ranking of quantification pipelines based on the subsampled data was highly concordant with that based on the original data. Therefore, we conclude that subsampling is a valid approach to facilitating efficient quantification pipeline selection using RNA-seq data.
I. INTRODUCTION
Next-generation sequencing (NGS) is an established technology that determines DNA or RNA sequences in biological samples. Raw data generated by NGS are short sequence reads, or reads for short, that contain readings of DNA or cDNA fragments. RNA-seq is a major application of NGS that studies transcriptomes. To capture the highly dynamic transcriptome, one popular approach is to study gene and transcript expression among various biological conditions or samples collected at various time points [1] . A typical bioinformatics pipeline for RNA-seq expression analysis includes sequence mapping, followed by expression quantification. Some quantification algorithms require transcriptomic mapping information while others require genomic mapping information. Thus, in our study, the term "quantification pipeline" represents a pipeline from the sequence mapping step to the expression quantification step.
From the bioinformatics perspective, one fundamental question for RNA-seq users is that which quantification pipeline(s) they should use to estimate gene and transcript expression that is closer to the truth. To address this question, given many available quantification pipelines, systematic evaluation is necessary, and pipeline recommendation has to be explicit. Multiple researchers have conducted comparative studies for several widely used quantification pipelines [2, 3] . However, NGS is a fast-evolving technology, and sequencing data characteristics are protocol-and library-dependent [4, 5] . Therefore, the selection of quantification pipeline(s) should not be solely based on existing knowledge or evidence, but rather customized for each RNA-seq dataset.
To achieve this objective, a comprehensive investigation is necessary for each RNA-seq dataset, but such effort may be impossible due to large data volume and computational demand. Thus, we propose a subsampling approach to speed up the search process for quantification pipeline(s) that can produce the most accurate expression estimates. The speedup mainly results from a reduction in sequencing depth (i.e., the total number of reads available for downstream analysis). Several studies have investigated the impact of sequencing depth on RNA-seq applications and have concluded that higher sequencing depth will lead to more accurate results [6, 7] . Therefore, our approach may lead to less accurate expression estimates that may in turn influence the selection of quantification pipeline(s). However, because expression estimates for high expression genes are less sensitive to noise, we hypothesize that by focusing on evaluating these high expression genes, our approach should still be valid.
II. METHODS

A. Experimental Design
The workflow of the entire study is shown in Figure 1 .(A). We incorporate three RNA-seq datasets, one simulated and two real, in our study. The "Quantification Pipelines" module quantifies both subsampled [ Figure 1 .(A), path (1)] and original [ Figure 1 .(A), path (2)] RNA-seq data. Input information for the "Evaluation" module includes estimated expression generated by the "Quantification Pipelines" module and true expression derived from the simulated dataset. Both estimated expression and true expression contain expression profiles for both subsampled data and original data. The detailed workflow of the "Quantification Pipelines" module is shown in Figure 1. (B). We use TopHat [8] and Bowtie [9] to map RNA-seq data to the reference genome and transcriptome, respectively. Since TopHat builds on an algorithm similar to Bowtie, we effectively minimize the impact of sequence mapping-induced variations on expression estimates. It is necessary to include both the genomic mapping tool (i.e., TopHat) and the transcriptomic mapping tool (i.e., Bowtie) because some quantification tools (e.g., Cufflinks [10] , HTSeq [11] , and MISO [12] ) require genomic mapping information, while others (e.g., RSEM [2] , eXpress [13] , and MMSEQ [14] ) require transcriptomic mapping information.
B. Datasets
We downloaded the hg19 reference genome and the RefSeq genome annotation from the UCSC Genome Browser and the UCSC Table Browser, respectively. We generated the simulated dataset using the rlsim-simNGS pipeline [15] The two real datasets are the SEQC (i.e., Sequencing Quality Control) dataset [16] and the NCBI Sequence Reads Archive SRP043090 dataset [17] . Both were generated by the Illumina HiSeq 2000 sequencing system. The SEQC dataset sequenced two well-established reference RNA samples, UHRR (Universal Human Reference RNA) and HBRR (Human Brain Reference RNA), each of which contains four technical replicates with around 104 million read pairs each and the read length of 100 bp. The SRP043090 dataset sequenced samples in two biological conditions, each of which contains three biological replicates with around 60 million read pairs each and the read length of 100 bp.
C. Subsampling Approach
For Illumina sequencing, RNA-seq reads stored in an unprocessed FASTQ file are randomly listed in terms of their originating transcripts. Thus, uniform subsampling should retain such the randomness. Many studies have investigated the impact of sequencing depth on various RNA-seq applications. However, no consensus has been reached regarding adequate sequencing depth for each RNA-seq application. Thus, in this preliminary study, we subsample RNA-seq data by a factor of five (i.e., sample one fifth of reads from the original data) that will retain at least ten million read pairs in each subsampled data for all our RNA-seq datasets.
D. Quantification Pipelines
We apply Cufflinks, HTSeq, and MISO to quantify gene and transcript expression using genomic mapping information produced by TopHat. The Cufflinks package generates gene and transcript expression estimates in terms of both read counts and FPKM-normalized expression. The HTSeq package generates read counts for only genes, while MISO provides read counts for both genes and transcripts. In contrast, we apply RSEM, eXpress, and MMSEQ to quantify gene and transcript expression using transcriptomic mapping information produced by Bowtie. These three quantification tools generate gene and transcript expression estimates in terms of both read counts and FPKM-normalized expression. RSEM and eXpress also provide TPM-normalized (i.e., transcripts per million) expression estimates. For read counts estimated by all the six tools, we apply the same RLE (relative log expression) normalization method [18] to minimize potential variations induced by the normalization process. All programs were executed with default parameters.
E. Evaluation Metrics
We design two evaluation metrics to assess the validity of our approach. The first metric is based on gene or transcript detection, and the second metric evaluates the deviation between expression estimates. To investigate the impact of expression levels on the two metrics, we stratify all genes into four equally sized bins: high expression (75 -100 percentiles), medium-high expression (50 -75 percentiles), medium-low expression (25 -50 percentiles), and low expression (0 -25 percentiles). For calculation that involves simulated data, we stratify genes based on their true expression. For other cases, we stratify genes based on the sum of RLE-normalized expression across all samples and pipelines. On the basis of our experimental design, we evaluate each metric under the following two scenarios: "TrueVsEst," which compares true expression to estimated expression, and "OrigVsSub," which compares expression derived from the original data to expression derived from the subsampled data.
For the first metric, gene or transcript detection, we define that expression levels greater than zero are detected. For the TrueVsEst scenario, we treat true expression as the ground truth, and then calculate the number of true positives (TP), true negatives (TN), false positives (FP), and false negatives (FN). As an example, the FP is defined as a gene undetected in the true but detected in the estimated expression. For the OrigVsSub scenario, we treat the expression derived from the original data as the ground truth, and then compute the number of TP, TN, FP, and FN accordingly. We use the total number of TP, TN, FP, and FN to calculate sensitivity, precision, and accuracy for gene detection. The aforementioned evaluation process is directly applicable to the transcript case.
For the second metric, deviation between expression estimates, since measures of absolute deviation are scale-dependent, to compensate scales among genes, we first normalize gene expression to the same scale, remove extreme deviations, and finally compute deviation metrics. For the TrueVsEst scenario, we use Equation (1) to normalize estimated expression relative to true expression:
where , is the normalized expression for a gene , , is the estimated expression for the gene , and , is the true expression for the gene . Once we compute the normalized expression for all genes, we filter out the upper and lower 0.05% extremes (i.e., retain 99.9% of the data) so that the deviation metrics will not be affected by extreme cases. After normalization, the deviation for each gene is defined as , minus one. The deviation metrics we adopt are root-mean-square deviation (RMSD) and median absolute deviation (MAD). For the OrigVsSub scenario, we use Equation (2) to normalize expression based on subsampled data relative to expression based on original data:
where , is the expression estimate for a gene using the subsampled data, , is the expression estimate for the gene using the original data, and is a user-defined subsampling factor ( = 5 in our study). After normalization, the rest of the evaluation process is the same as that in the TrueVsEst scenario. The aforementioned evaluation process is directly applicable to the transcript case.
III. RESULTS AND DISCUSSION
In our study, we proposed to use the subsampling approach to efficiently select quantification pipeline(s) for each RNA-seq dataset. The success of this approach depends on two premises: (1) expression estimates derived from the subsampled data need to be close to those derived from the original data, and (2) quantification pipelines selected using the subsampled data need to be similar to those using the original data. In this section, we will investigate our results and demonstrate evidence in support of the two premises.
A. Gene or Transcript Detection
Following the method we described in Section II.E, we calculated sensitivity, precision, and accuracy for gene or transcript detection under the two scenarios, TrueVsEst and OrigVsSub. Focusing on high expression genes/transcripts (i.e., 75 -100 percentiles), Figure 2 demonstrates the distribution of these measures for the TrueVsEst scenario using the simulated dataset, and Figure 3 shows results for the OrigVsSub scenario using all the three datasets.
As demonstrated in Figure 2 , sensitivity, precision, and accuracy calculated using the subsampled data (black boxes) were very close to those calculated using the original data (blue triangles) with less than 0.1% difference for all statistics and pipelines. In addition, the ranking of quantification pipelines (i.e., eXpress > MMSEQ > RSEM > MISO > Cufflinks > HTSeq, where "A > B" indicates A outperformed B) using the subsampled data was the same as that using the original data. These observations supported the two premises we described in the beginning of this section.
Figure 3 aims to demonstrate that expression estimates derived from the subsampled data were very close to those derived from the original data (i.e., the postulated ground truth) measured by the gene or transcript detection accuracy. For gene detection, all quantification pipelines achieved nearly 100% accuracy for all the three datasets. For transcript detection, the accuracy still achieved 97% or above for the two real datasets with the "eXpress" pipeline consistently outperformed others. These observations supported the first premise we described in the beginning of this section.
B. Deviation Analysis
We calculated RMSD and MAD under the two scenarios. Focusing on high expression genes/transcripts (i.e., 75 -100 percentiles), Figure 4 shows the distribution of RMSD and MAD for the TrueVsEst scenario using the simulated dataset, and Figure 5 demonstrates results for the OrigVsSub scenario using all the three datasets.
As shown in Figure 4 , RMSD and MAD calculated using the subsampled data (black boxes) were very close to those calculated using the original data (blue triangles) with the transcript-level analysis tended to overestimate deviations using the subsampled data. In addition, the ranking of quantification pipelines using the subsampled data was the same as that using the original data for gene-level evaluation, though the RMSD-based ranking slightly differed from the MAD-based ranking. For transcript-level evaluation, the two rankings were not exactly the same because of prevalent overestimated deviations. However, the two rankings were still highly concordant. These observations supported the two premises we described in the beginning of this section.
Finally, Figure 5 aims to demonstrate that expression estimates derived from the subsampled data were very close to those derived from the original data (i.e., the postulated ground truth) measured by the MAD. For most quantification pipelines and all the datasets, the MAD was under 0.03 (or 3%) and 0.06 (or 6%) for gene-level and transcript-level deviation analysis, respectively. This observation supported the first premise we described in the beginning of this section. 
IV. CONCLUSIONS
With the need to identify the most suitable quantification pipeline(s) for each RNA-seq dataset, we proposed the subsampling approach that can help researchers achieve this goal more efficiently. Through our preliminary investigation, we found that statistics based on high expression genes in the subsampled data were close to those based on the original data for the two metrics we implemented. In addition, the ranking of pipeline performance using the subsampled data was concordant with that using the original data. Currently, our study presents some limitations that closely relate to our future work as follows: (1) the two metrics we implemented required references, either ground-truth expression from the simulated dataset or expression estimates based on the original data. Thus, we will need to implement reference-free metrics such as the coefficient of variation and between-replicate fold-changes; (2) we executed all programs with default parameters, so we will need to investigate the effect of parameter selection on the rankings of quantification pipelines; and (3) we chose to subsample data by a factor of five so that we can retain an adequate sequencing depth for downstream analysis. This was an arbitrary choice, so we will evaluate whether different subsampling factors will lead to similar conclusions. 
